Valeant Pharmaceuticals (VRX) Reiterated Top Pick at Mizuho Securities; PT to $111
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- GlobalFoundries and Marvell expand SiGe capacity for optical networking
Left for Dead Valeant Pharma (VRX) Is Up 30% In a Week
November 23, 2015 10:43 AM ESTShort seller target Valeant Pharma (NYSE: VRX) is continuing to rally sharply off oversold conditions following a few modest positives over the past week or so:
Citi launched coverage on the... MoreValeant Pharma (VRX) Adds to Strong Gains; Sets Sights on $90
November 20, 2015 1:10 PM ESTShort seller target Valeant Pharma (NYSE: VRX) is seeing notably strength again today on the back of yesterday's 16% move up. Shares last traded up 5.6% to $88.73.
Yesterday, Citi endorsed the credit with an Overweight rating and today Mizuho reiterated it as a top pick, saying "the stock appears to have bottomed."
... MoreValeant Pharma (VRX) to Host December 16 Investor Day
November 20, 2015 9:00 AM ESTShort seller target Valeant Pharma (NYSE: VRX) announced it will will be hosting an Investor Day on December 16, 2015 where the Company will be providing updated financial guidance, discussing certain business operations and highlighting certain R&D programs.
Conference Call and Webcast... More
Valeant Pharma (VRX) Surges as Co's Debt Gets Endorsed
November 19, 2015 10:05 AM ESTBeaten down Valeant Pharma (NYSE: VRX) is up 9% early to $79, benefiting from today's Overweight rating on the company's debt at Citi.
The firm cited product diversification and strong FCF generation.
... MoreCiti Credit Research Sees Opportunity in Valeant (VRX), Initiates With Overweight Rating (MNK) (ENDP)
November 19, 2015 9:28 AM ESTCiti Credit Research initiated coverage on Valeant Pharma (NYSE: VRX) with an Overweight rating. Analysts noted its global footprint, product diversification and strong FCF generation. Peers Mallinckrodt (NYSE: MNK) and Endo (NASDAQ: ENDP) were... More
